These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 28107779

  • 1. Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy.
    Sun LJ, Sun YN, Shan JP, Jiang GR.
    J Diabetes Investig; 2017 Jul; 8(4):609-618. PubMed ID: 28107779
    [Abstract] [Full Text] [Related]

  • 2. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA, Gariani K, Martin PY.
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [Abstract] [Full Text] [Related]

  • 3. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF.
    Cochrane Database Syst Rev; 2014 Apr 29; (4):CD007004. PubMed ID: 24782282
    [Abstract] [Full Text] [Related]

  • 4. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
    Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M.
    Nephrol Dial Transplant; 2013 Nov 29; 28(11):2823-33. PubMed ID: 24009294
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
    An J, Niu F, Sim JJ.
    Pharmacotherapy; 2021 Dec 29; 41(12):998-1008. PubMed ID: 34655484
    [Abstract] [Full Text] [Related]

  • 6. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD: A Network Meta-Analysis.
    Luo X, Xu J, Zhou S, Xue C, Chen Z, Mao Z.
    Clin J Am Soc Nephrol; 2023 Aug 01; 18(8):1019-1030. PubMed ID: 37256921
    [Abstract] [Full Text] [Related]

  • 7. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF.
    Cochrane Database Syst Rev; 2009 Jul 08; (3):CD007004. PubMed ID: 19588415
    [Abstract] [Full Text] [Related]

  • 8. Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
    Liu X, Ma L, Li Z.
    J Endocrinol Invest; 2020 Jul 08; 43(7):959-972. PubMed ID: 31939197
    [Abstract] [Full Text] [Related]

  • 9. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy.
    Ren F, Tang L, Cai Y, Yuan X, Huang W, Luo L, Zhou J, Zheng Y.
    Ren Fail; 2015 May 08; 37(4):548-61. PubMed ID: 25707526
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis.
    Tian ML, Shen Y, Sun ZL, Zha Y.
    Int Urol Nephrol; 2015 May 08; 47(5):815-22. PubMed ID: 25862237
    [Abstract] [Full Text] [Related]

  • 11. Renal Protective Effects of Combination of Diltiazem and ACEI/ARB on the Progression of Diabetic Nephropathy: Randomized Controlled Trial.
    Krairittichai U, Sarinnapakorn V, Mahannopkul R, Ainwan P.
    J Med Assoc Thai; 2017 Feb 08; 100 Suppl 1():S40-7. PubMed ID: 29927180
    [Abstract] [Full Text] [Related]

  • 12. Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease.
    Mavrakanas TA, Giannetti N, Sapir-Pichhadze R, Alam A.
    Cardiorenal Med; 2020 Feb 08; 10(1):32-41. PubMed ID: 31665724
    [Abstract] [Full Text] [Related]

  • 13. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM, Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group.
    JAMA; 2015 Sep 01; 314(9):884-94. PubMed ID: 26325557
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in diabetic nephropathy: a systematic review and meta-analysis.
    Du YH, Guan CJ, Li LY, Gan P.
    Ann Palliat Med; 2022 Mar 01; 11(3):1093-1101. PubMed ID: 35365039
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
    Ji Y, Yang K, Xiao B, Lin J, Zhao Q, Bhuva MS, Yang H.
    J Cell Biochem; 2019 Mar 01; 120(3):3689-3695. PubMed ID: 30270542
    [Abstract] [Full Text] [Related]

  • 16. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J.
    Diabet Med; 2007 May 01; 24(5):486-93. PubMed ID: 17367311
    [Abstract] [Full Text] [Related]

  • 17. Effects of adding Rheum officinale to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal function in patients with chronic renal failure: A meta-analysis of randomized controlled trials
.
    Yang Y, Ma YP, Zhang Z, Dai PL, Li P, Li WG.
    Clin Nephrol; 2018 Jun 01; 89(6):445-454. PubMed ID: 29208203
    [Abstract] [Full Text] [Related]

  • 18. Comparative efficacy of seven Chinese patent medicines for early diabetic kidney disease: A Bayesian network meta-analysis.
    Zhao J, Ai J, Mo C, Shi W, Meng L.
    Complement Ther Med; 2022 Aug 01; 67():102831. PubMed ID: 35398481
    [Abstract] [Full Text] [Related]

  • 19. [Meta analysis of the efficacy and safety of combined treatment with ARB and ACEI on diabetic kidney disease].
    Gu J, Han L, Liu Q.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun 01; 38(6):623-30. PubMed ID: 23828705
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y, Huang R, Kavanagh J, Li L, Zeng X, Li Y, Fu P.
    Am J Cardiovasc Drugs; 2019 Jun 01; 19(3):259-286. PubMed ID: 30737754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.